Kishoyian, GabrielNjagi, Eliud N. M.Orinda, George O.Kimani, Francis T.Thiongo, KevinMatoke-Muhia, Damaris2023-08-212023-08-212020Kishoyian G, Njagi ENM, Orinda GO, Kimani FT, Thiongo K, Matoke- Muhia D (2021). Efficacy of artemisinin– lumefantrine for treatment of uncomplicated malaria after more than a decade of its use in Kenya. Epidemiology and Infection 149, e27, 1–9. https://doi.org/10.1017/ S0950268820003167https://doi.org/10.1017/ S0950268820003167http://ir-library.ku.ac.ke/handle/123456789/26863articleBackground. The resistance of Plasmodium falciparum to antimalarial drugs remains a major impairment in the treatment and eradication of malaria globally. Following the introduction of artemisinin-based combination therapy (ACT), there have been reports of delayed parasite clearance. In Kenya, artemether–lumefantrine (AL) is the recommended first-line treatment of uncomplicated malaria. This study sought to assess the efficacy of AL after a decade of use as the preferred method of managing malarial infections in Kenya. We assessed clinical and parasitological responses of children under 5 years between May and November 2015 in Chulaimbo sub-County, Kisumu, Kenya. Patients aged between 6 and 60 months with uncomplicated P. falciparum mono-infection, confirmed through microscopy, were enrolled in the study. The patients were admitted at the facility for 3 days, treated with a standard dose of AL, and then put under observation for the next 28 days for the assessment of clinical and parasitological responses. Of the 90 patients enrolled, 14 were lost to follow-up while 76 were followed through to the end of the study period. Seventy-five patients (98.7%) cleared the parasitaemia within a period of 48 h while one patient (1.3%) cleared on day 3. There was 100% adequate clinical and parasitological response. All the patients cleared the parasites on day 3 and there were no re-infections observed during the stated follow-up period. This study, therefore, concludes that AL is highly efficacious in clearing P. falciparum parasites in children aged ≥6 and ≤60 months. The study, however, underscores the need for continued monitoring of the drug to forestall both gradual ineffectiveness and possible resistance to the drug in all target users.enArtemether–lumefantrineefficacyfalciparum malariaKenyaArticle